VR Logo

GlycoMimetics Inc. (GLYC) download report


Healthcare | Biotechnology & Pharma Research

GlycoMimetics Inc. (GLYC) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.

IPO Date: 10-Jan-2014

CEO, Pres & Director: Mr. Harout Semerjian

Sr. VP & CFO: Mr. Brian M. Hahn

Listing: NASDAQ: GLYC

Country: United States

Headquarters: Rockville, MD

Website: https://www.glycomimetics.com

Key Facts

Market cap: $32.25 Mln

Revenue (TTM): $0.09 Mln

Earnings (TTM): $-63.81 Mln

Cash: $76.52 Mln

Total Debt: $1.68 Mln

Insider's Holding: 1.98%

Liquidity: Low

52 Week range: $0.51 - 2.50

Shares outstanding: 52,392,400

10 Years Aggregate:

  • CFO: $-290.08 Mln
  • EBITDA: $-258.55 Mln
  • Net Profit: $-316.55 Mln

Stock Performance

Time Period GlycoMimetics (GLYC) S&P BSE Sensex S&P Small-Cap 600
YTD-60.42-9.18-18.76
1 month-9.52-4.78-7.98
3 months-50.00-9.66-13.63
1 Year-75.430.81-17.17
3 Years-63.7010.336.11
5 Years-44.8411.345.88
10 Years--11.749.84
As on 01-Jul-2022
Year GlycoMimetics (GLYC) S&P Small-Cap 600 S&P BSE Sensex
2021-61.7025.2721.99
2020-28.929.5715.75
2019-44.1420.8614.38
2018-43.42-9.705.87
2017175.2511.7327.91
20166.6424.741.95
2015-20.56-3.36-5.03